Dupixent vs Otezla
A side-by-side look at two autoimmune medications advertised on TV. Informational only — not medical advice.
Maintained by TVPills Editorial Team · Site updated November 4, 2026 (not a product-label review)
| Attribute | US Dupixent | US Otezla |
|---|---|---|
| Generic name | dupilumab Unverified catalogue summary (Generic name) for Dupixent in US; not checked against current local product information. | apremilast Unverified catalogue summary (Generic name) for Otezla in US; not checked against current local product information. |
| Drug class | See official local label Unverified catalogue summary (Drug class) for Dupixent in US; not checked against current local product information. | See official local label Unverified catalogue summary (Drug class) for Otezla in US; not checked against current local product information. |
| Treats | See official local label Unverified catalogue summary (Treats) for Dupixent in US; not checked against current local product information. | Plaque psoriasis, psoriatic arthritis, oral ulcers associated with Behçet's disease Unverified catalogue summary (Treats) for Otezla in US; not checked against current local product information. |
| Category | Autoimmune Unverified catalogue summary (Category) for Dupixent in US; not checked against current local product information. | Autoimmune Unverified catalogue summary (Category) for Otezla in US; not checked against current local product information. |
| Manufacturer | Regeneron Pharmaceuticals, Inc. Unverified catalogue summary (Manufacturer) for Dupixent in US; not checked against current local product information. | Amgen Unverified catalogue summary (Manufacturer) for Otezla in US; not checked against current local product information. |
| Year approved | — Unverified catalogue summary (Year approved) for Dupixent in US; not checked against current local product information. | — Unverified catalogue summary (Year approved) for Otezla in US; not checked against current local product information. |
| Catalogue warning level | Safety summary withheld — check official label Unverified catalogue summary (Catalogue warning level) for Dupixent in US; not checked against current local product information. | Safety summary withheld — check official label Unverified catalogue summary (Catalogue warning level) for Otezla in US; not checked against current local product information. |
| Est. TV ad spend | $390M | $110M |
| Side effects and serious risks | — Unverified catalogue summary (Side effects and serious risks) for Dupixent in US; not checked against current local product information. | — Unverified catalogue summary (Side effects and serious risks) for Otezla in US; not checked against current local product information. |
Sources and editorial standards
Use the current DailyMed labels to verify approved uses, boxed warnings, and side effects for each medication. Label results can differ by product, strength, and formulation.
Page updated November 4, 2026; the linked resources have not necessarily been reviewed on this date.
Frequently asked questions
Is Dupixent or Otezla better?
This directory does not compare clinical effectiveness or safety. Listing Dupixent and Otezla together does not establish shared approved indications, equivalence or suitability as substitutes. Consult the correct local labels and your prescriber.
What's the difference between Dupixent and Otezla?
The table shows catalogue identification and estimated advertising information for Dupixent and Otezla, not a verified medical comparison. Medical descriptions, mechanisms and safety summaries are withheld.
Which one spends more on TV ads?
Dupixent has the larger estimated TV advertising budget of the two.